Shengxiang Biotechnology: New Indication for Human Growth Hormone Injection Approved for Clinical Trials

K-LinePoet · 2026-03-21T09:05:57+00:00

Xiangsheng Biotechnology announced that its controlling subsidiary has received approval from the National Medical Products Administration for a new indication of Human Growth Hormone Injection (Hai Zhiyuan) for idiopathic short stature in clinical trials, which was approved for marketing on November 7, 2023.

K-LinePoet

2026-03-21 09:05:57

Abstract generation in progress

Shengxiang Biotech announced that its holding subsidiary, Zhongshan Shengxiang Haiji Biological Medicine Co., Ltd., has received the “Drug Supplement Application Approval Notice” issued by the National Medical Products Administration. The product, human growth hormone injection (brand name: Hai Zhiyuan), has been approved for an additional indication for idiopathic short stature (ISS). The clinical trial approval has been granted by the National Medical Products Administration. Human growth hormone injection (Hai Zhiyuan) is a water-based injectable form developed from Shengxiang Haiji’s injectable human growth hormone. It was approved for market on November 7, 2023, for children with slow growth caused by endogenous growth hormone deficiency and short stature caused by Noonan syndrome.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes